Affiliation:
1. Interventional Department, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou City, 310022, China
2. Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou City, 310022, China
Abstract
Fuzheng Kangai decoction (FZKA) has been preliminarily proved to be effective in hepatocellular carcinoma (HCC). This study plans to investigate the clear role of FZKA on HCC progression. After establishing a HCC tumor-bearing mice model and treated with FZKA, the volumes and weights
of HCC tumor were monitored, and tumor pathology was analyzed by HE staining. The expression of the molecules related to angiogenesis, apoptosis and angiogenesis in tumor tissues were detected by immunohistochemistry, Western blot and qRT-PCR assays. In addition, HCC cells were administrated
with increasing concentrations of FZKA. Then the cell proliferation, migration and invasion ability were tested. In HCC tumor bearing mice, it was found that FZKA significantly decreased the tumor volumes, weights, aggravated tumor pathological damage, reduced VEGF, CD34, Bcl-2 expression,
but promoted the expression of Bax, cleaved caspase 3, Cyt-C in tumor tissues. Moreover, in vitro experiments demonstrated that FZKA co-incubation suppressed the proliferation, migration and invasion ability of HCC cells. This study demonstrated that FZKA has the potential to inhibit
HCC progression by promoting apoptosis and inhibiting angiogenesis.
Publisher
American Scientific Publishers
Subject
Pharmaceutical Science,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献